Author:
Liu He-Nan,Zhu Ying,Chi Yuan,Zhang Yao,Li Xun,Wen Wen,Shan Li-Shen,Wang Ya-Tao,Dai Bing
Reference74 articles.
1. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, W.L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science (New York, N.Y.), 235 (1987) 177-182.
2. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications;Iqbal;Molecular Biology International,2014
3. Lapatinib plus capecitabine for HER2-positive advanced breast cancer;Geyer;The New England Journal of Medicine,2006
4. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer;Burstein;Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology,2010
5. The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer;Sirhan;Military Medical Research,2022